BRPI0911118A2 - composto e compisições como moduladores de atividade de gpr119 - Google Patents

composto e compisições como moduladores de atividade de gpr119

Info

Publication number: BRPI0911118A2
Authority: BR; Brazil
Prior art keywords: compsions; compound; activity modulators; gpr119 activity; gpr119
Prior art date: 2008-04-07

Application number

BRPI0911118A

Other languages

English (en)

Inventor

Christopher Cow

Robert Epple

Original Assignee

Irm Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-04-07

Filing date

2009-04-03

Publication date

2015-10-06

2009-04-03 Application filed by Irm Llc filed Critical Irm Llc

2015-10-06 Publication of BRPI0911118A2 publication Critical patent/BRPI0911118A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Hematology (AREA)
Cardiology (AREA)
Immunology (AREA)
Obesity (AREA)
Physical Education & Sports Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Ophthalmology & Optometry (AREA)
Orthopedic Medicine & Surgery (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Reproductive Health (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Transplantation (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Gynecology & Obstetrics (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

BRPI0911118A 2008-04-07 2009-04-03 composto e compisições como moduladores de atividade de gpr119 BRPI0911118A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US4310008P	2008-04-07	2008-04-07
PCT/US2009/039506 WO2009126535A1 (en)	2008-04-07	2009-04-03	Compounds and compositions as modulators of gpr119 activity

Publications (1)

Publication Number	Publication Date
BRPI0911118A2 true BRPI0911118A2 (pt)	2015-10-06

Family

ID=40718535

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0911118A BRPI0911118A2 (pt)	2008-04-07	2009-04-03	composto e compisições como moduladores de atividade de gpr119

Country Status (11)

Country	Link
US (1)	US20110263557A1 (pt)
EP (1)	EP2271619A1 (pt)
JP (1)	JP2011516557A (pt)
KR (2)	KR20100137561A (pt)
CN (1)	CN102056900A (pt)
AU (1)	AU2009233984B2 (pt)
BR (1)	BRPI0911118A2 (pt)
CA (1)	CA2720950A1 (pt)
EA (1)	EA018703B1 (pt)
MX (1)	MX2010011070A (pt)
WO (1)	WO2009126535A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2295816T3 (es)	2003-01-14	2008-04-16	Arena Pharmaceuticals, Inc.	Derivados arilo y heteroarilo 1,2,3-trisustituidos como moduladores del metabolismo, y profilaxis y tratamiento de transtornos relacionados con los mismos, tales como la diabetes y la hiperglucemia.
MX2010005298A (es) *	2007-11-16	2010-06-30	Rigel Pharmaceuticals Inc	Compuestos de carboxamida, sulfonamida y amina para trastornos metabolicos.
KR101432396B1 (ko) *	2009-06-18	2014-08-20	카딜라 핼쓰캐어 리미티드	신규한 ｇｐｒ 119 작용물질
AR077214A1 (es)	2009-06-24	2011-08-10	Neurocrine Biosciences Inc	Heterociclos nitrogenados y composiciones farmaceuticas que los contienen
NZ596445A (en)	2009-06-24	2013-04-26	Boehringer Ingelheim Int	New compounds, pharmaceutical composition and methods relating thereto
CN102686579A (zh) *	2009-10-09	2012-09-19	Irm责任有限公司	作为gpr119活性调节剂的化合物和组合物
US8912206B2 (en)	2009-11-23	2014-12-16	Merck Sharp & Dohme Corp.	Pyrimidine ether derivatives and methods of use thereof
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011113947A1 (en)	2010-03-18	2011-09-22	Boehringer Ingelheim International Gmbh	Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
EP2619198A1 (en)	2010-09-22	2013-07-31	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en) *	2011-06-08	2012-12-13	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en)	2011-09-27	2015-10-21	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CA2878625A1 (en)	2012-07-11	2014-01-16	Elcelyx Therapeutics, Inc.	Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US9783533B2 (en)	2014-01-06	2017-10-10	Rhizen Pharmaceuticals Sa	Glutaminase inhibitors
PL3242666T3 (pl)	2015-01-06	2025-02-17	Arena Pharmaceuticals, Inc.	Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
JP6838744B2 (ja)	2015-06-22	2021-03-03	アリーナファーマシューティカルズ，インコーポレイテッド	Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
AU2018220521A1 (en)	2017-02-16	2019-09-05	Arena Pharmaceuticals, Inc.	Compounds and methods for treatment of primary biliary cholangitis
KR102859841B1 (ko)	2018-06-06	2025-09-12	아레나 파마슈티칼스, 인크.	S1p1 수용체와 관련된 병태의 치료 방법
PH12022550852A1 (en)	2019-10-07	2023-05-03	Kallyope Inc	Gpr119 agonists
CA3173731A1 (en)	2020-02-28	2021-09-02	Kallyope, Inc.	Gpr40 agonists
KR20230012597A (ko)	2020-05-19	2023-01-26	칼리오페, 인크.	Ampk 활성화제
AU2021297323A1 (en)	2020-06-26	2023-02-16	Kallyope, Inc.	AMPK activators
EP4320129A1 (en) *	2021-04-06	2024-02-14	Kallyope, Inc.	Gpr119 agonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE60126785T2 (de) *	2000-08-08	2007-10-25	Ortho-Mcneil Pharmaceutical, Inc.	Nicht-imidazol aryloxypiperidine als h3 rezeptor liganden
GB0224084D0 (en) *	2002-10-16	2002-11-27	Glaxo Group Ltd	Novel compounds
AR045047A1 (es) *	2003-07-11	2005-10-12	Arena Pharm Inc	Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
AU2006215080B2 (en) *	2005-02-17	2011-03-10	Astellas Pharma Inc.	Pyridyl non-aromatic nitrogenated heterocyclic-1-carboxylate ester derivative
KR20080087833A (ko) *	2005-12-21	2008-10-01	쉐링 코포레이션	히스타민 ｈ３ 길항제로서 유용한 페녹시피페리딘 및 이의유사체
GB0607196D0 (en) *	2006-04-11	2006-05-17	Prosidion Ltd	G-protein coupled receptor agonists
CN101801954B (zh) *	2007-09-20	2013-10-09	Irm责任有限公司	作为gpr119活性调节剂的化合物和组合物
CN102686579A (zh) *	2009-10-09	2012-09-19	Irm责任有限公司	作为gpr119活性调节剂的化合物和组合物

2009
- 2009-04-03 EP EP09729907A patent/EP2271619A1/en not_active Withdrawn
- 2009-04-03 KR KR1020107024936A patent/KR20100137561A/ko not_active Ceased
- 2009-04-03 MX MX2010011070A patent/MX2010011070A/es unknown
- 2009-04-03 CN CN2009801210288A patent/CN102056900A/zh active Pending
- 2009-04-03 BR BRPI0911118A patent/BRPI0911118A2/pt not_active IP Right Cessation
- 2009-04-03 EA EA201001595A patent/EA018703B1/ru not_active IP Right Cessation
- 2009-04-03 KR KR1020137027483A patent/KR20130132653A/ko not_active Ceased
- 2009-04-03 CA CA2720950A patent/CA2720950A1/en not_active Abandoned
- 2009-04-03 JP JP2011504095A patent/JP2011516557A/ja not_active Ceased
- 2009-04-03 WO PCT/US2009/039506 patent/WO2009126535A1/en not_active Ceased
- 2009-04-03 AU AU2009233984A patent/AU2009233984B2/en not_active Ceased
- 2009-04-03 US US12/936,453 patent/US20110263557A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2720950A1 (en)	2009-10-15
MX2010011070A (es)	2011-01-20
KR20100137561A (ko)	2010-12-30
WO2009126535A1 (en)	2009-10-15
JP2011516557A (ja)	2011-05-26
US20110263557A1 (en)	2011-10-27
EP2271619A1 (en)	2011-01-12
AU2009233984A1 (en)	2009-10-15
AU2009233984B2 (en)	2012-11-22
KR20130132653A (ko)	2013-12-04
EA018703B1 (ru)	2013-10-30
CN102056900A (zh)	2011-05-11
EA201001595A1 (ru)	2011-04-29

Publication	Publication Date	Title
BRPI0911118A2 (pt)	2015-10-06	composto e compisições como moduladores de atividade de gpr119
BRPI0907584A2 (pt)	2015-07-21	Composto e composições como moduladores de atividade de gpr119
BRPI0915867A2 (pt)	2017-06-20	4-fenoximetilpiperidinas como moduladores de atividade de gpr119
BRPI0912431A2 (pt)	2015-07-28	Combinações de substâncias ativas sinergísticas
BRPI0915918A2 (pt)	2018-07-10	análogos de piridona e piridazona como moduladores de gpr119
BRPI0922845A2 (pt)	2015-12-29	pirazol-4-n-alcoxicarboxamidas como microbiocidas
BRPI0913117A2 (pt)	2016-01-05	imidazopiridina e análogos relacionados como moduladores de sirtuína
BRPI0817211A2 (pt)	2017-05-16	composto composições como moduladores da atividade de gpr119
BRPI0808192A2 (pt)	2019-09-24	composto e composições como moduladores de atividades de gpr119
BRPI0921327A2 (pt)	2015-08-25	Combinação de herbicida-protetor
BRPI0917017A2 (pt)	2016-02-16	inibidores de pirrol de s-nitrosoglutationa redutase como agentes terapêuticos
BRPI0920832A2 (pt)	2015-12-22	cabines de tratores
BRPI0909656A2 (pt)	2015-07-28	Microencapsulamento
BRPI0922597A8 (pt)	2018-09-25	ftalazinona e análogos relacionados como moduladores de sirtuína
BRPI0919625A2 (pt)	2015-12-01	piriridina, piridina bicíclica e análogos relacionados como moduladores de sirtuína
BRPI0914006A2 (pt)	2015-10-27	benzimidazóis e análogos relacionados como moduladores de sirtuína
BRPI1008939A2 (pt)	2016-03-15	2-mercaptoquinolina-3-carboxamidas substituídas como moduladores de kncq2/3.
BRPI0922464A2 (pt)	2015-08-11	Combinações de compostos ativos
EP2320221A4 (en)	2013-08-28	ELECTRODE
BRPI0812753A2 (pt)	2014-09-30	Combinações de substância ativas acaricidas
BRPI0908851A2 (pt)	2017-05-30	compostos e composições como moduladores da atividades de gpr119
BRPI0918344A2 (pt)	2015-12-15	composição catalítica
BRPI0822058A2 (pt)	2015-06-23	Derivados de 5-oxo-3-pirrolidinacarboxamida como moduladores de p2x7
BRPI0906959A2 (pt)	2015-07-14	Variantes de celulase com inibição reduzida por glicose
LT3150178T (lt)	2021-08-10	Stimuliavimo aparatas

Legal Events

Date	Code	Title	Description
2016-09-13	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 7A ANUIDADE.
2017-01-10	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.